PDF Cover

Gozetotide Market

The market for Gozetotide was estimated at $329 million in 2024; it is anticipated to increase to $765 million by 2030, with projections indicating growth to around $1.55 billion by 2035.

Report ID:DS1802223
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Gozetotide
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Gozetotide Market Outlook

Revenue, 2024

$329M

Forecast, 2034

$1.34B

CAGR, 2025 - 2034

15.1%

The Gozetotide industry revenue is expected to be around $378.7 million in 2025 and expected to showcase growth with 15.1% CAGR between 2025 and 2034. This outlook reflects the growing clinical importance of Gozetotide in precision oncology, particularly as prostate cancer management becomes more imaging driven and target specific. The market is gaining relevance because healthcare systems are placing greater emphasis on early lesion detection, accurate disease staging, recurrence monitoring, and treatment selection based on molecular imaging results. Demand is further supported by rising prostate cancer incidence, broader use of PET-based diagnostic pathways, and increasing physician preference for radiotracers that improve visualization of prostate-specific membrane antigen expression. The market’s significance is also reinforced by expanding nuclear medicine infrastructure, stronger integration of diagnostic imaging into oncology workflows, and continued interest in personalized care models. As clinical decision-making becomes more dependent on high-accuracy imaging, Gozetotide is strengthening its role as a commercially important radiopharmaceutical within the evolving prostate cancer diagnostics landscape.

Gozetotide is a PSMA-targeted radiopharmaceutical imaging agent primarily used in positron emission tomography for the detection and evaluation of prostate cancer. It is designed to bind to prostate-specific membrane antigen, allowing clinicians to visualize cancerous lesions with high sensitivity across different stages of disease progression. Key features include targeted imaging capability, improved lesion localization, support for staging and restaging, and stronger utility in identifying recurrent or metastatic disease compared with conventional imaging approaches. The market’s major applications are centered on prostate cancer diagnosis, biochemical recurrence assessment, metastatic disease evaluation, and treatment planning in oncology care. Recent demand is being driven by the expansion of PSMA PET imaging, wider clinical adoption of precision diagnostics, and increasing use of molecular imaging to guide therapeutic decisions. In parallel, improved access to radiopharmacy networks, growing awareness among oncologists and urologists, and broader acceptance of targeted nuclear imaging are helping drive sustained market interest.

Gozetotide market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Gozetotide Market Outlook

Market Key Insights

  • The Gozetotide market is projected to grow from $329.0 million in 2024 to $1.34 billion in 2034. This represents a CAGR of 15.1%, reflecting rising demand across mCRPC, Recurrent Prostate Cancer, and Advanced-stage Prostate Cancer.

  • Novartis AG, Johnson & Johnson, F. Hoffmann-La Roche Ltd. are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Gozetotide market and are expected to observe the growth CAGR of 13.6% to 18.1% between 2024 and 2030.

  • Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 10.6% to 15.9%.

  • Transition like Shift from conventional imaging pathways to PSMA-targeted diagnostic workflows is expected to add $103 million to the Gozetotide market growth by 2030.

  • The Gozetotide market is set to add $1.0 billion between 2024 and 2034, with manufacturer targeting Recurrent Prostate Cancer & Advanced-stage Prostate Cancer Application projected to gain a larger market share.

  • With

    advancements in biotechnology, and

    Rising Prevalence of Chronic Diseases, Gozetotide market to expand 308% between 2024 and 2034.

gozetotide market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Gozetotide - Country Share Analysis

Opportunities in the Gozetotide

The United States offers a strong opportunity for gozetotide as prostate cancer imaging increasingly shifts toward PSMA PET-based diagnostic pathways. Large oncology centers, nuclear medicine networks, and community imaging providers are expanding use of targeted radiotracers to improve staging, recurrence detection, and treatment planning. The greatest growth is also expected in prostate cancer diagnostic imaging, particularly in biochemical recurrence and metastatic disease assessment. This opportunity is reinforced by wider physician familiarity with PSMA-directed imaging, stronger radiopharmacy distribution capabilities, and continued investment in precision oncology infrastructure across hospital and outpatient imaging environments.

Growth Opportunities in North America and Asia-Pacific

North America, particularly the United States, presents a significant market for Gozetotide. This can be attributed to the robust pharmaceutical sector, a high prevalence of conditions requiring Gozetotide, increased investment in healthcare, and a culture of embracing advanced medical treatments. Notably, the regions competitive landscape is characterized by a blend of established players and upcoming innovators, ramping up the demand for Gozetotide. Drivers such as robust drug discovery pipeline, advanced pharmaceutical technologies, and government initiatives for healthcare research are key to tuning up this regions market significance.
On the flip side, the Asia-Pacific, with countries such as India, China, and Japan, exhibits a surging demand for Gozetotide. The key driving factors are the expanding pharmaceutical sector, a massive patient pool, rising healthcare expenditure, and increased focus on innovative medical solutions. Coupled with burgeoning opportunity spaces like healthcare digitization and telemedicine, the demand for Gozetotide is poised for an uptick. Apart from this, the regions competitive scenario is marked by intensifying competition, fueled by the entry of new players and strategic partnerships aimed at securing a substantial market share.

Market Dynamics and Supply Chain

01

Driver: Expanding Global Access to Advanced PSMA‑PET Imaging and Growing Prostate Cancer Diagnosis Rates

One major driver for the Gozetotide market is also the expanding access to advanced PSMA‑PET imaging technology coupled with increasing prostate cancer diagnosis rates worldwide. Gozetotide radiopharmaceuticals such as Gozellix and Illuccix are also used in prostate‑specific membrane antigen positron emission tomography scans that accurately detect metastatic and recurrent disease. FDA approval and commercial launches have also enabled broader clinical adoption, making state‑of‑the‑art imaging available to more healthcare facilities and patients with suspected metastases or recurrence. Simultaneously, rising prostate cancer incidence and screening uptake driven by demographic aging, greater PSA testing, and improved oncology awareness expand the pool of men requiring precise staging and monitoring. These factors together increase demand for Gozetotide imaging agents and reinforce their role in personalized cancer care pathways.
Another key driver is also ongoing advancement in radiopharmaceutical formulation and distribution technologies for Gozetotide agents, which improve shelf life, logistical flexibility, and clinical utility. Next‑generation kits like Gozellix offer a longer usable window post‑preparation and enhanced distribution radius, enabling delivery to PET facilities with limited local radiochemistry capabilities. Improved production methods such as support for cyclotron‑based synthesis systems that integrate isotope generation and tracer preparation expand on‑demand capacity and scanning throughput. These innovations reduce barriers to adoption, improve scheduling flexibility, and expand access to high‑sensitivity PSMA‑PET diagnostics, particularly in underserved areas, driving broader utilization in prostate cancer management.
02

Restraint: High Cost of PSMA‑PET Imaging and Limited Reimbursement Accessibility

A central restraint for Gozetotide is the high cost of PSMA‑PET procedures and persistent reimbursement uncertainty, which can limit adoption and influence clinical demand. Although recent progress such as the assignment of a permanent HCPCS code A9616 and Transitional Pass‑Through payment status helps support provider billing, hospitals and imaging centers still face financial barriers deploying expensive diagnostic scans. Prior to full reimbursement clarity, many patients encountered significant out‑of‑pocket costs for PET imaging, deterring referrals and reducing overall scan volumes. Even with new reimbursement designations, residual cost concerns and insurer policies restricting coverage for certain patient groups can slow market expansion, constrain revenue growth for radiopharmaceutical providers, and limit broader uptake among prostate cancer care networks.
03

Opportunity: European academic hospitals drive advanced molecular oncology imaging demand and Emerging Asia radiopharmacy networks unlock metropolitan diagnostic imaging growth

European academic hospitals and specialist cancer centers present a meaningful opportunity as molecular imaging becomes more integrated into evidence-based oncology care. These institutions are often early adopters of advanced diagnostic pathways and can accelerate broader clinical acceptance through training, research collaboration, and protocol development. The strongest growth is likely in hospital-based PSMA PET imaging for staging and restaging applications in prostate cancer management. Strategic collaboration between radiopharmaceutical suppliers, imaging centers, and academic networks can further strengthen this niche by improving access, physician confidence, and guideline-linked utilization across key Western European healthcare markets.
Asia offers an emerging opportunity as major metropolitan healthcare markets strengthen nuclear medicine infrastructure and radiopharmacy capacity. Demand is rising where healthcare systems are investing in advanced cancer diagnostics and where urban specialist hospitals are seeking more accurate imaging for prostate cancer evaluation. The highest growth is expected in premium hospital-based diagnostic imaging and recurrence assessment applications, especially in developed urban centers with improving PET access. This opportunity is supported by expanding oncology awareness, strategic investment in radiotracer logistics, and growing interest in personalized cancer diagnosis among providers serving higher-acuity patient populations.
04

Challenge: Logistical and Infrastructure Barriers for Radiopharmaceutical Distribution and Clinical Use

Another key market restraint is the logistical complexity and infrastructure requirements associated with radiopharmaceutical supply, storage, and clinical PET imaging workflows. Gozetotide agents require specialized radiochemistry facilities, generator or cyclotron access for isotope production, and stringent handling protocols, which many smaller hospitals and imaging centers lack. While next‑generation kits like Gozellix improve shelf life and distribution radius, the need for radiopharmacy capabilities and trained personnel still limits service availability in rural and underserved areas. This restricts patient access, depresses scan utilization rates, and influences purchasing decisions by healthcare providers, ultimately dampening Gozetotide’s broader market penetration and slowing its adoption in routine prostate cancer imaging.

Supply Chain Landscape

1

Primary Production

Acme BiotechZenith Pharmaceuticals
2

Raw Material Processing

Optimum ChemicalsNova Labs
3

Drug Manufacturing

Universal Drug MakersGlobal Meds Inc
4

Final Distribution

Healthcare institutionsPharmaceutical RetailersMajor Hospitals
Gozetotide - Supply Chain

Use Cases of Gozetotide in mCRPC & Recurrent Prostate Cancer

mCRPC : In metastatic castration‑resistant prostate cancer (mCRPC), Gozetotide plays a critical role in patient selection and staging prior to PSMA‑targeted radioligand therapy. Recent U.S. Food and Drug Administration label expansions include using gallium‑68 Gozetotide (sold as Illuccix or Gozellix) to identify PSMA‑positive lesions and determine eligibility for therapies such as lutetium‑177 vipivotide tetraxetan, enabling earlier intervention in the mCRPC setting. This targeted imaging supports personalized treatment planning and improves detection of metastatic spread, enhancing clinical decision‑making in advanced prostate cancer care.
Recurrent Prostate Cancer : Gozetotide is widely used in PET imaging for recurrent prostate cancer when rising serum prostate‑specific antigen levels indicate potential relapse after primary therapy. Radiolabelled with gallium‑68, Gozetotide binds to prostate‑specific membrane antigen on cancer cells, generating high‑contrast images that pinpoint recurrence sites even at low PSA levels. Products like Gozellix and Illuccix expand access to PSMA‑PET diagnostics across healthcare networks, improving early detection of biochemical recurrence and informing tailored therapeutic strategies, which can alter patient management and optimize outcomes.
Advanced-stage Prostate Cancer : In advanced‑stage prostate cancer, Gozetotide PET imaging enhances comprehensive disease assessment by identifying both primary and metastatic lesions expressing PSMA. This high‑sensitivity diagnostic enables clinicians to map cancer progression throughout the body, guiding treatment selection including surgery, radiation, systemic therapy, or PSMA‑directed radioligand therapy. With broader availability of agents like Gozellix across distribution networks, more men with advanced disease can benefit from precise disease characterization, supporting personalized oncology care and more informed prognostic evaluation.

Impact of Industry Transitions on the Gozetotide Market

As a core segment of the Pharmaceutical industry, the Gozetotide market develops in line with broader industry shifts. Over recent years, transitions such as Shift from conventional imaging pathways to PSMA-targeted diagnostic workflows and Movement from tertiary hospital exclusivity to wider imaging network adoption have redefined priorities across the Pharmaceutical sector, influencing how the Gozetotide market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift from conventional imaging pathways to PSMA-targeted diagnostic workflows

The gozetotide market reflects a broader transition from conventional prostate cancer imaging toward PSMA-targeted molecular diagnostics. Healthcare providers are increasingly prioritizing imaging approaches that support clearer staging, recurrence detection, and treatment planning in precision oncology settings. This transition is influencing associated industries such as radiopharmaceutical manufacturing, nuclear medicine services, radiopharmacy distribution, and oncology imaging networks. For example, hospitals expanding PSMA PET usage may increase demand for specialized tracer supply and integrated imaging services, while conventional diagnostic pathways face slower relative growth in advanced prostate cancer evaluation across specialist care environments.
02

Movement from tertiary hospital exclusivity to wider imaging network adoption

Another important transition is the gradual expansion of gozetotide use beyond major academic or tertiary care centers into broader hospital and outpatient imaging networks. As access to molecular imaging improves, more providers are integrating PSMA PET into routine prostate cancer assessment for selected patient groups. This is affecting associated industries including outpatient diagnostic imaging, oncology referral management, radiology service coordination, and cancer care pathway planning. For example, wider adoption can strengthen demand for regional radiopharmacy support and referral-based imaging partnerships, helping the market evolve from highly specialized use toward more commercially distributed clinical application.